# Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness

> **NCT03566069** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shalvata Mental Health Center** · enrollment: 120 (estimated)

## Conditions studied

- Severe Mental Illness

## Interventions

- **DRUG:** Intranasal Oxytocin
- **OTHER:** Intranasal Placebo

## Key facts

- **NCT ID:** NCT03566069
- **Lead sponsor:** Shalvata Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-01
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03566069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03566069, "Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03566069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*